Quantcast

Transcatheter aortic valve replacement: The year in review 2016

Research paper by Kishore J. Harjai MD, Cindy L. Grines MD, Jean‐Michael Paradis MD, Susheel Kodali MD

Indexed on: 04 Mar '17Published on: 02 Mar '17Published in: Journal of Interventional Cardiology



Abstract

Transcatheter aortic valve replacement (TAVR) continued to make major strides in 2016, simultaneously expanding its application to lower risk patients as well as more technically challenging subsets of patients with aortic stenosis (AS). The two major accomplishments this year were the establishment of TAVR as the preferred treatment strategy over surgical aortic valve replacement (SAVR) in intermediate risk patients, and initial signals that TAVR and SAVR may be clinically equivalent in low-risk populations. Meanwhile, there is continued expansion of TAVR to challenging clinical subsets (bicuspid aortic valve [BAV], patients with concomitant advanced coronary artery disease [CAD], and failed surgical bioprostheses), and encouraging initial experiences with newer transcatheter heart valve systems. This paper summarizes the major research studies published on TAVR in 2016.